Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VA and VAC/VA in Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma
NCT05304585Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Aug 2022
- Primary completion
- Jun 2030
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
Phase 3, open-label trial of vincristine sulfate liposome injection, actinomycin D and cyclophosphamide in rhabdomyosarcoma (RMS) (3 arms), sponsored by Children's Oncology Group. Primary endpoint: Failure Free Survival at 3 years. Started Aug 2022; status: recruiting.
02
Drugs
vincristine sulfate liposome injectionactinomycin Dcyclophosphamide
03
Conditions
rhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on NCT05304585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304585.